The global patient telemonitoring systems market is witnessing rapid innovation as connected devices and IoT transform patient monitoring practices. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Patient Telemonitoring Systems Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Patient Telemonitoring Systems Market, by Offering / Solution Type
8.1.1. Hardware-centric solutions (device + basic connectivity)
8.1.1.1. Market Revenue and Forecast
8.1.2. Software-first platforms / clinical-grade SaaS (data aggregation, analytics, EHR integration)
8.1.2.1. Market Revenue and Forecast
8.1.3. End-to-end managed RPM services (devices + connectivity + clinical monitoring / nurse triage)
8.1.3.1. Market Revenue and Forecast
8.1.4. Integrated virtual care suites (RPM + telehealth visits + CCM / disease management)
8.1.4.1. Market Revenue and Forecast
8.1.5. Point solutions (single-device monitoring, e.g., CGM or single-lead ECG)
8.1.5.1. Market Revenue and Forecast
9.1. Patient Telemonitoring Systems Market, by Clinical Function / Monitored Parameter
9.1.1. Cardiac (ECG, arrhythmia, heart rate, heart failure, weight monitoring)
9.1.1.1. Market Revenue and Forecast
9.1.2. Respiratory (SpOâ‚‚, respiratory rate, spirometry, COPD)
9.1.2.1. Market Revenue and Forecast
9.1.3. Metabolic / Diabetes (CGM, BG)
9.1.3.1. Market Revenue and Forecast
9.1.4. Blood pressure & vascular (home BP monitoring, hypertension management)
9.1.4.1. Market Revenue and Forecast
9.1.5. Multiphysiologic / Multiparameter (combinations for complex chronic care)
9.1.5.1. Market Revenue and Forecast
9.1.6. Neuro / Rehab (movement, seizures)
9.1.6.1. Market Revenue and Forecast
9.1.7. Maternal & fetal monitoring (home pregnancy / postpartum vitals)
9.1.7.1. Market Revenue and Forecast
10.1. Patient Telemonitoring Systems Market, by End-User / Buyer
10.1.1. Hospitals & health systems (readmission reduction, post-acute)
10.1.1.1. Market Revenue and Forecast
10.1.2. Primary care & ambulatory clinics (chronic disease mgmt)
10.1.2.1. Market Revenue and Forecast
10.1.3. Home health agencies & hospice
10.1.3.1. Market Revenue and Forecast
10.1.4. Payers & value-based care organizations (risk contracts)
10.1.4.1. Market Revenue and Forecast
10.1.5. Employers / wellness programs
10.1.5.1. Market Revenue and Forecast
10.1.6. Clinical research / CROs (decentralized clinical trials)
10.1.6.1. Market Revenue and Forecast
11.1. Patient Telemonitoring Systems Market, by Deployment Model / Commercial Model
11.1.1. CapEx device purchase + software license
11.1.1.1. Market Revenue and Forecast
11.1.2. Device-as-a-service (bundled rental + subscription)
11.1.2.1. Market Revenue and Forecast
11.1.3. Per-patient-per-month (PPPM) SaaS + device reimbursement model
11.1.3.1. Market Revenue and Forecast
11.1.4. Fee-for-service / CPT reimbursement (US RPM CPT codes)
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Offering / Solution Type
12.1.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.1.3. Market Revenue and Forecast, by End-User / Buyer
12.1.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.1.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.1.5.3. Market Revenue and Forecast, by End-User / Buyer
12.1.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Offering / Solution Type
12.1.6.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.1.6.3. Market Revenue and Forecast, by End-User / Buyer
12.1.6.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.2. Europe
12.2.1. Market Revenue and Forecast, by Offering / Solution Type
12.2.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.2.3. Market Revenue and Forecast, by End-User / Buyer
12.2.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.2.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.2.5.3. Market Revenue and Forecast, by End-User / Buyer
12.2.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Offering / Solution Type
12.2.6.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.2.6.3. Market Revenue and Forecast, by End-User / Buyer
12.2.6.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Offering / Solution Type
12.2.7.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.2.7.3. Market Revenue and Forecast, by End-User / Buyer
12.2.7.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Offering / Solution Type
12.2.8.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.2.8.3. Market Revenue and Forecast, by End-User / Buyer
12.2.8.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.3. APAC
12.3.1. Market Revenue and Forecast, by Offering / Solution Type
12.3.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.3.3. Market Revenue and Forecast, by End-User / Buyer
12.3.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.3.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.3.5.3. Market Revenue and Forecast, by End-User / Buyer
12.3.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Offering / Solution Type
12.3.6.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.3.6.3. Market Revenue and Forecast, by End-User / Buyer
12.3.6.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Offering / Solution Type
12.3.7.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.3.7.3. Market Revenue and Forecast, by End-User / Buyer
12.3.7.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Offering / Solution Type
12.3.8.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.3.8.3. Market Revenue and Forecast, by End-User / Buyer
12.3.8.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.4. MEA
12.4.1. Market Revenue and Forecast, by Offering / Solution Type
12.4.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.4.3. Market Revenue and Forecast, by End-User / Buyer
12.4.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.4.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.4.5.3. Market Revenue and Forecast, by End-User / Buyer
12.4.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Offering / Solution Type
12.4.6.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.4.6.3. Market Revenue and Forecast, by End-User / Buyer
12.4.6.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Offering / Solution Type
12.4.7.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.4.7.3. Market Revenue and Forecast, by End-User / Buyer
12.4.7.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Offering / Solution Type
12.4.8.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.4.8.3. Market Revenue and Forecast, by End-User / Buyer
12.4.8.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.5.3. Market Revenue and Forecast, by End-User / Buyer
12.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Offering / Solution Type
12.5.5.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.5.5.3. Market Revenue and Forecast, by End-User / Buyer
12.5.5.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Offering / Solution Type
12.5.6.2. Market Revenue and Forecast, by Clinical Function / Monitored Parameter
12.5.6.3. Market Revenue and Forecast, by End-User / Buyer
12.5.6.4. Market Revenue and Forecast, by Deployment Model / Commercial Model
13.1. Philips
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Medtronic plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. ResMed Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Biofourmis
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Omron Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Teladoc Health
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Vivify Health
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. ResMed Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abbott Laboratories
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Dexcom, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description